On Friday, October 13, 2023, our Managing Director Ms. Jennifer Che participated as a panelist in InvestHK’s event “Unlock the Life & Health Sciences Potential through Innovation”. Keynote speeches focused on Hong Kong’s strengths in the life sciences (good medical schools, strong research) and also Hong Kong’s challenges bridging the gap between fundamental research and commercial products. The panel discussion centered around “Hong Kong as a life and health technology innovation hub.” Moderated by Dr. Josephine Au from InvestHK, the other panel members included Ir. Eric Chan from Hong Kong Cyberport Management Co. Ltd., Dr. Grace Lau from HKSTP Institute of Translational Research, Ms. Simone Song from ORI Capital and Mr. Henry Yau from HKU Clinical Trials Centre. Jennifer shared about Hong Kong’s uniqueness as a place to find IP experts having international qualifications as well as cross-border experience. She also expressed frustration at how many HK companies still don’t value the importance of good IP strategy (and are unwilling to invest in such matters), which hurts them when they enter the international stage down the road. It was an enlightening discussion and valuable to hear various people’s thoughts on the future of Hong Kong in the life & health sciences area.
我們過去活動
Recommended Insights
China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines
2021年10月19日The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]
閱讀更多 >
Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent
2025年2月4日The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
閱讀更多 >
Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?
2020年7月14日This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
閱讀更多 >
China Proposes New Examination Guidelines for Utility Models
2022年11月24日The Utility Model (UM) in China has always been a popular choice for patent filing due to its relatively low cost and speed of prosecution. The UM prosecution only includes a preliminary examination, which is essentially a mini (stripped down) version of an invention application’s substantive examination.[1] With the simplified examination process, UMs are typically […]
閱讀更多 >